The sample sizes for tumour subtypes, while still large, were, therefore, much smaller than were available for analyses of breast cancer risk overall, particularly for ER-positive breast cancer in BRCA1 carriers and ER-negative breast cancer in BRCA2 carriers. The gene discussed is BRCA2; the disease is breast carcinoma.